Vitamin D Reduces Thrombosis In Cancer Patients Clinical Trial Demonstrates Unanticipated Benefit A clinical trial of a biologically active metabolite of Vitamin D3 demonstrated an unanticipated reduction of thrombosis in cancer patients. Thrombosis is a serious complication in advanced cancers and affects between 15 and 20 per cent of all cancer patients. Dr. Peter Venner, medical oncologist at the Alberta Cancer Board's Cross Cancer Institute, presented the finding today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia. In a randomized trial involving 250 patients with advanced prostate cancer in 48 clinical sites, those receiving high-dose calcitriol (DN-101) along with Docetaxel experienced a significant reduction in both venous and arterial thromboses compared to patients receiving a placebo and Docetaxel. Calcitriol is a naturally occurring hormone and the biologically active form of Vitamin D. Full story: http://www.psa-rising.com/med/side_effects/vitD_v_thromosis.html June 2006 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.